ESPAC-3, ESPAC-3(v2) logo

ESPAC-3, ESPAC-3(v2)

ADJUVANT CHEMOTHERAPIES IN RESECTABLE PANCREATIC CANCER

ESPAC-3, ESPAC-3(v2)

ADJUVANT CHEMOTHERAPIES IN RESECTABLE PANCREATIC CANCER
Funding CR:UK
Portfolio Cancer
Interventions Medicine
Randomised Yes
Status Closed
Start Date 07-Jul-2000

Pancreatic cancer is one of the major causes of cancer death in Central and Northern European countries as well as in North America, Australasia and Japan 1. Initial treatment involves surgical resection Despite recent improvements in resection rates for localised pancreatic cancer, long-term survival following Surgery alone remains poor with a median of 11-15 months, 2-year survival of 20-40% and 5-year survival of around 10% 2, 3. ESPAC-3 was formulated as a result of the ESPAC-1 study.

Publications

  • Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer.
    1. https://www.ncbi.nlm.nih.gov/pubmed/22782416